Read more

May 10, 2024
3 min watch
Save

VIDEO: Neurotech’s NT-501 shows promise in slowing macular telangiectasia progression

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Richard Small, CEO of Neurotech Pharmaceuticals, gives an update on NT-501, the company’s encapsulated cell therapy for macular telangiectasia.

The company recently submitted a license application to the FDA for the therapy, which delivers genetically modified therapeutic factors to the back of the eye.

“By delivering [ciliary neurotrophic factor] over a long period of time, we keep the photoreceptors healthy, and thus slow down the progression of the disease,” Small said.

He also previewed two phase 3 registration studies, which showed statistically significant results for slowing progression of the disease.